Researchers have engineered a strain of spirulina that produces usable vitamin B12 at levels matching beef, potentially transforming how billions of people access this essential nutrient. The breakthrough addresses a decades-old problem that has limited spirulina's value as a nutritional supplement.
Spirulina, a filamentous cyanobacterium grown worldwide as a protein-rich food, contains abundant B12-like compounds. But most forms are pseudocobalamin, an inactive analog the human body cannot absorb or utilize. This mismatch has frustrated nutritionists and made spirulina unreliable for B12-deficient populations, particularly vegans, the elderly, and people in low-income regions.
The research team controlled the light wavelengths used during algae cultivation to shift the microbial metabolism toward producing cyanocobalamin, the bioactive form humans require. This photosynthetic tuning produced spirulina with B12 levels reaching 1.5 to 5 micrograms per gram of dry weight. A single serving of beef contains roughly 2 to 4 micrograms. The engineered spirulina therefore delivers comparable B12 in a plant-based format.
Vitamin B12 deficiency remains a public health concern affecting an estimated 6 percent of people under 60 and up to 20 percent of those over 60. Insufficiency causes neurological damage, anemia, and cognitive decline when untreated. Vegans and vegetarians face particular risk because B12 appears naturally only in animal products and fermented foods. Regions lacking refrigeration or reliable supply chains struggle to distribute fortified foods and supplements.
Spirulina offers advantages as a B12 source. It grows rapidly in controlled systems, requires minimal arable land, and produces complete protein. The research team developed a carbon-neutral cultivation method using renewable energy, making production climate-friendly. Spirulina thrives in saline water unsuitable for crops, reducing freshwater pressure in water-stressed regions.
The light-control method represents a significant optimization. Rather than genetic modification, researchers manipulated environmental conditions to influence the algae's own metabolic pathways. This approach avoids regulatory complexity surrounding genetically engineered food organisms in many countries. The cultivated spirulina maintained stable B12 production across multiple growing cycles, suggesting commercial viability.
However, several questions remain unresolved. The research did not evaluate bioavailability in human subjects. Test-tube measurements of B12 concentration differ from what humans actually absorb through digestion. Gastric pH, intestinal bacteria, and individual metabolism affect absorption rates for both beef and spirulina. Clinical trials comparing B12 uptake from the engineered spirulina to conventional sources would strengthen claims.
Scaling production presents another challenge. Current systems remain laboratory-scale. Moving to industrial bioreactors requires validating that light-control precision translates to mass production. Manufacturing costs and consumer acceptance also factor into real-world adoption.
The work opens pathways for addressing nutritional gaps in food systems. If human studies confirm bioavailability, engineered spirulina could serve vulnerable populations in developing nations, where B12 deficiency clusters and refrigeration remains limited. It also appeals to vegans seeking whole-food sources rather than synthetic supplements. Further research will determine whether this carbon-neutral approach becomes part of the nutritional toolkit.